Status:
COMPLETED
First in Human Study of an Anti-IFN Gamma Monoclonal Antibody in Healthy Volunteers
Lead Sponsor:
Swedish Orphan Biovitrum
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safety, pharmacodynamic and pharmacokinetic profiles of a novel therapeutic drug when administered to healthy volunteers.
Eligibility Criteria
Inclusion
- healthy adults between 18 and 50 years old
- non smokers
- able to adhere to study protocol requirements
Exclusion
- any abnormal clinical safety laboratory parameters
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01459562
Start Date
September 1 2011
End Date
January 1 2013
Last Update
August 9 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
HMR
London, United Kingdom
2
ICON
Manchester, United Kingdom